Signed outside: A surface marker system for transgenic cytoplasmic proteins

Gene Therapy

Volumn 17, Issue 10, 2010, Pages 1193-1199

  Wohlgensinger, V ^a   Seger, R ^a   Ryan, M D ^b   Reichenbach, J ^a   Siler, U ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

LNGFR; chronic granulomatous disease; marker protein; NADPH oxidase; p47phox

Indexed keywords

CELL PROTEIN; MEMBRANE PROTEIN; NERVE GROWTH FACTOR RECEPTOR; OLIGOPEPTIDE; PROTEIN P47; PROTEIN P47PHOX LOW AFFINITY NERVE GROWTH FACTOR RECEPTOR FOOT AND MOUTH DISEASE VIRUS 2A PEPTIDE COMPLEX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; DRUG DETERMINATION; FLUORESCENCE ACTIVATED CELL SORTING; GRANULOCYTE; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL DETECTION; T LYMPHOCYTE;

ANIMALS; BIOLOGICAL MARKERS; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; NADPH OXIDASE; RECEPTORS, NERVE GROWTH FACTOR; TRANSGENES;

MURINAE; MUS;

EID: 77958020895     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.73     Document Type: Article

References (22)

1. Curnutte JT, Orkin SH, Dinauer MC. Genetic disorders of phagocyte function. In: The Molecular Basis of Blood Disease. Saunders: London, 1994, pp 493-540.
2. Roos D, van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. Microbes Infect 2003; 5: 1307-1315.
3. Singh J, Freeling M, Lisch D. A position effect on the heritability of epigenetic silencing. PLoS Genet 2008; 4: e1000216.
4. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibody to deplete neutro-phils in mice. J Leukoc Biol 2008; 83: 64-70.
5. Jarrosson-Wuilleme L, Goujon C, Bernaud J, Rigal D, Darlix JL, Cimarelli A. Transduction of nondividing human macro-phages with gammaretrovirus-derived vectors. J Virol 2006; 80: 1152-1159.
6. Halpin C, Cooke SE, Barakate A, El Amrani A, Ryan MD. Self-processing 2A-polyproteins\-a system for co-ordinate expression of multiple proteins in transgenic plants. Plant J 1999; 17: 453-459.
7. Funston GM, Kallioinen SE, de Felipe P, Ryan MD, Iggo RD. Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping. J Gen Virol 2008; 89: 389-396.
8. Donnelly ML, Gani D, Flint M, Monaghan S, Ryan MD. The cleavage activities of aphthovirus and cardiovirus 2A proteins. J Gen Virol 1997; 78: 13-21.
9. Donnelly ML, Hughes LE, Luke G, Mendoza H, ten Dam E, Gani D et al. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J Gen Virol 2001; 82: 1027-1041.
10. Ibrahimi A, Velde GV, Reumers V, Toelen J, Thiry I, Vandeputte C et al. Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum Gene Ther 2009; 20: 845-860.
11. Chinnasamy D, Milsom MD, Shaffer J, Neuenfeldt J, Shaaban AF, Margison GP et al. Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Vi rol J 2006; 3: 14.
12. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol 2003; 21: 117-122. (Pubitemid 36293768)
13. Klump H, Schiedlmeier B, Vogt B, Ryan M, Ostertag W, Baum C. Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy. Gene Therapy 2001; 8: 811-817.
14. Ouellet DL, Plante I, Boissonneault V, Ayari C, Provost P. Refractoriness of hepatitis C virus internal ribosome entry site to processing by Dicer in vivo. J Negat Results Biomed 2009; 8: 8.
15. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
16. Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003; 9: 367-369.
17. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2: 331-341.
18. Fehse B, Roeder I. Insertional mutagenesis and clonal dominance: biological and statistical considerations. Gene Therapy 2008; 15: 143-153.
19. Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Yet al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008; 111: 4297-4308.
20. Recchia A, Bonini C, Magnani Z, Urbinati F, Sartori D, Muraro S et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted Tcells. Proc Natl Acad Sci USA 2006; 103: 1457-1462.
21. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005; 105: 4235-4246.
22. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.